EGFR and non-small cell lung carcinoma: Given the low frequency of A763_Y764insFQEA (3%–8%) (Riess et al., 2018; Yang et al., 2020; Yang G et al., 2021; Geng et al., 2022) and D770delinsGY (2.0%–4.8%) (Yang et al., 2020; Yang J et al., 2021) variants, their response to diverse EGFR TKIs in the real world NSCLC cohorts is ambiguous.